

Bionano Corporate Overview

August 2026

bionano™




Cautionary Note Regarding Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our expectations regarding market adoption of our products; our commercial prospects and future financial and operating results; and our ability to meet our stated goals and commercial opportunities, including our full year and third quarter 2026 guidance. Each of these forward-looking statements involves risks and uncertainties. Accordingly, investors and prospective investors are cautioned not to place undue reliance on these forward-looking statements as they involve inherent risk and uncertainty (both general and specific) and should note that they are provided as a general guide only and should not be relied on as an indication or guarantee of future performance. There are a number of important factors that could cause the actual results to differ materially from those expressed in any forward-looking statement made by us. These factors include, but are not limited to: our ability to improve our margins, extend our cash runway and reach a potential pathway to profitability; our ability to retire our debt at maturity; our ability to continue as a going concern as disclosed in our filings with the SEC, which requires us to manage costs and obtain significant additional financing to fund our strategic plans and commercialization efforts; our ability to execute on our strategy and achieve our objectives; the impact and utility of our cost savings initiative and our recent financing; our ability to continue to drive OGM (as defined above) adoption by potential customers for routine use in genomic analysis; the impact, or lack thereof, of Category I CPT codes to accelerate or increase the adoption of OGM; continued research, presentations and publications involving OGM and its utility compared to traditional cytogenetics and our technologies; the impact of our Stratys™ system and VIA™ software to increase throughput and simplify analysis of OGM data; our ability to drive adoption of OGM and our technology solutions; our ability to further deploy new products and applications for our technology platforms; our expectations and beliefs regarding future growth of the business and the markets in which we operate; our ability to consummate any strategic alternatives including the risk that if we fail to obtain additional financing we may seek relief under applicable insolvency laws; the size and growth potential of the markets for our products, and our ability to serve those markets; the rate and degree of market acceptance of our products; our ability to manage the growth of our business and integrate acquired businesses; our ability to expand our commercial organization to address effectively existing and new markets that we intend to target; the impact from future regulatory, judicial, and legislative changes or developments in the U.S. and foreign countries; our ability to compete effectively in a competitive industry; the introduction of competitive technologies or improvements in existing technologies and the success of any such technologies; the performance of our third-party contract sales organizations, suppliers and manufacturers; our ability to attract and retain key scientific or management personnel; the accuracy of our estimates regarding expenses, future revenues, reimbursement rates, capital requirements and needs for additional financing; the impact of adverse geopolitical and macroeconomic developments, such as recent and future bank failures, ongoing international conflicts, and related sanctions, regional or global pandemics, inflation, tariffs, increased cost of goods, supply chain issues, and global financial market conditions on our business and operations, as well as the business or operations of our suppliers, customers, manufacturers, research partners and other third parties with whom we conduct business and our expectations with respect to the duration of such impacts and the resulting effects on our business; our ability to realize the anticipated benefits and synergies of our prior and any future acquisitions or other strategic transactions; our ability to attract collaborators and strategic partnerships; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission (“SEC”), including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2025, any subsequently filed Quarterly Reports on Form 10-Q and in other filings subsequently made by us with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise, except as may be required by law.

GAAP reconciliation of adjusted financial measures can be found in the Appendix and our earnings release.

Bionano is among the leaders transforming pathology from its analog roots into a more digital future




We pioneered the introduction of OGM, optical genome mapping

Optical genome mapping (OGM) is a method for structural variant (SV) detection that replaces multiple traditional cytogenetic techniques

- OGM consolidates 3 legacy cytogenetic methods into one assay
- Complements sequencing as a new tool
- Consistently finds more actionable variants in days vs. weeks at a substantially lower cost

Large market opportunity to be captured with strategic focus on driving growth in utilization of consumables supported by routine users of OGM

- Targeting customers across academic medical centers and commercial reference labs
- Research applications include cancer, cell and gene therapy, and constitutional genetic disease
- Estimated global OGM TAM: \$10B and 10K labs running ~10M samples/year + 2.4M samples for cell and gene therapy



Al Luderer, PhD
Chairman &
Interim Chief
Executive Officer
Joined 2011



Mark Oldakowski
Chief Operating
Officer
Joined 2014



Alka Chaubey, PhD
Chief Medical
Officer
Joined 2020



Jonathan Dixon
General Counsel
Joined 2022



Mark Adamchak
VP Finance &
Accounting, PAO
Joined 2018

Traditional methods for SV detection are outdated & leave a significant number of questions unanswered

Traditional cytogenetics requires multiple methods
that are labor intense, time-consuming, repetitive & costly

Clinical utility of traditional cytogenetic analysis is severely limited



Karyotyping

Up to 4 weeks for results



FISH

(fluorescence *in-situ* hybridization)

4-6 different probes per sample & successive testing



Microarrays


Detect CNVs only

Only 50% of testing is useful for guiding therapy

As many as 20% of prognostic scores for Rx selection may be wrong


86% of cell & gene therapy programs are halted, due partly to limitations in genome analysis tools

Customers adopt our end-to-end solution for OGM to go from sample to interpreted report in as few as 3 days



*In development.
Full commercial release anticipated in 2026


VIA™ Software is also used widely as a stand-alone solution for visualization, interpretation & reporting of NGS and Microarray data



Isotachopheresis (ITP) on the Ionic™ System transforms NA isolation from FFPE for use in NGS



Bionano solutions address unmet needs across the genome variation size continuum in cytogenetics and sequencing



We focus on transforming cytogenetics to serve three key application areas with strong support from publications

Hematological malignancy

nature

THE UNIVERSITY OF TEXAS
**MD Anderson
Cancer Center**

- OGM prognostic scores were different for 17 to 21% of study subjects
- OGM revealed additional pathogenic variants in 13% of study subjects

<https://www.nature.com/articles/s41375-022-01652-8#Abs1>

Constitutional genetic disease

npj nature partner
journals

UCSF

- OGM findings resolved genetic diseases that were previously undiagnosed
- OGM resulted in incremental increase in diagnostic yield of 12% in rare disease cohort

<https://www.nature.com/articles/s41525-021-00241-5>

Cell & gene therapy

THE
**EMBO
JOURNAL**

SR-//iget

- OGM detected 11 nonrecurring SVs outside of the target locus
- OGM analysis showed that 20-50% of the edited cells expressing the rescued gene did not undergo precise editing

<https://www.embopress.org/doi/pdf/10.15252/embj.2023114188>

Effective Jan 1, 2026, a CPT code covering OGM in genetic disorders and a 47% price increase for code used for hematologic malignancies

AMA CPT Code for OGM in Constitutional Genetic Disorders (new in 2026)

Current Code #	81354
Code Type	NEW
Category	Molecular Pathology; Optical Genome Mapping
Long Code Descriptor	Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of structural and copy number variants, optical genome mapping (OGM)

Final payment determination effective Jan 1, 2026:
\$1,263.53

AMA CPT Code for OGM in Hematologic Malignancies (47% price increase in 2026)

Current Code #	81195
Code Type	NEW 2024; Payment reconsidered 2025
Category	Molecular Pathology; Optical Genome Mapping
Long Code Descriptor	Cytogenomic (genome-wide) analysis, hematologic malignancy, structural variants and copy number variants, optical genome mapping (OGM)


Reconsidered payment determination effective Jan 1, 2026:
\$1,853.22 (47% increase)

CPT = Current Procedural Terminology

Consumables revenue continued to grow in Q2 as a result of our strategy of focusing on routine users


Flowcells Sold

- In connection to new customer sales
- To existing customer base




Revenue Mix

- Other revenue
- Software revenue
- Consumables revenue




Pace of new publications in 2026 on track for record number by year end

117 new publications in Q2 2026
across a range of applications



New Publication CAGR (2020-2025): 28%

1,335 human clinical research genomes published
in Q2 2026 reaching 16,000+ in total




Published Genome CAGR (2021-2025): 30%+

Disciplined execution over last two years drove considerable improvements to cost structure in Q2


Decreased adjusted operating expenses¹
by 4% Q/Q in Q2 2026

Adjusted Operating Expenses Trend (\$M)



Improved adjusted gross margin¹ to 53%
in Q2 2026, compared to adjusted core gross
margin of 52%² in Q2 2025

Adjusted Core Gross Margin² Trend (%)



Q2 2026 Financial Results

\$8.2M

Q2 Revenue

+21%
vs. Q2'25

9,219


Q2 Flowcells
Sold

+27%
vs. Q2'25

53%


Q2 Adjusted
Gross Margin

+116 bps
vs. Q2'25



\$10.4M¹ cash, cash equivalents, and available-for-sale securities as of June 30, 2026

Strategic pillars





Thank you.

bionano™

Reconciliation of GAAP to Adjusted Financial Measures (Unaudited)

Bionano Genomics, Inc. Reconciliation of GAAP to Adjusted Financial Measures (Unaudited)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
GAAP gross margin:				
GAAP revenue	\$ 8,171	\$ 6,733	\$ 14,858	\$ 13,190
GAAP cost of revenue	3,857	3,256	7,292	6,774
GAAP gross profit	4,314	3,477	7,566	6,416
GAAP gross margin %	% 53	% 52	% 51	% 49
Adjusted gross margin: ¹				
GAAP revenue	\$ 8,171	\$ 6,733	\$ 14,858	\$ 13,190
GAAP cost of revenue	3,857	3,256	7,292	6,774
Stock-based compensation expense	(27)	(40)	(58)	(77)
Adjusted cost of revenue	3,830	3,216	7,234	6,697
Adjusted gross profit	4,341	3,517	7,624	6,493
Adjusted gross margin %	% 53	% 52	% 51	% 49
GAAP operating expense				
GAAP selling, general and administrative expense	\$ 8,544	\$ 8,346	\$ 16,554	\$ 17,379
Stock-based compensation expense	(872)	(880)	(1,433)	(2,180)
Intangible asset amortization	(1,340)	(1,340)	(2,680)	(2,680)
Transaction related expenses	(50)	(63)	(150)	(126)
Executive transition costs	(499)	—	(499)	—
Adjusted selling, general and administrative expense	5,783	6,063	11,792	12,393
GAAP research and development expense	\$ 2,988	\$ 2,931	\$ 6,127	\$ 5,299
Stock-based compensation expense	(71)	(160)	(149)	(410)
Adjusted research and development expense	2,917	2,771	5,978	4,889
Total adjusted operating expense	\$ 8,700	\$ 8,834	\$ 17,770	\$ 17,282

1. For all periods through Q3 2024, adjusted gross margin includes adjusted gross margin for discontinued services